KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares OutstandingShares Repurchased
Ratios

West Pharmaceutical Services (WST) EBIAT (2016 - 2026)

West Pharmaceutical Services has reported EBIAT over the past 18 years, most recently at $138.8 million for Q1 2026.

  • Quarterly EBIAT rose 54.57% to $138.8 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $542.7 million through Mar 2026, up 16.16% year-over-year, with the annual reading at $493.7 million for FY2025, 0.2% changed from the prior year.
  • EBIAT was $138.8 million for Q1 2026 at West Pharmaceutical Services, up from $132.1 million in the prior quarter.
  • Over five years, EBIAT peaked at $188.5 million in Q2 2022 and troughed at $89.8 million in Q1 2025.
  • The 5-year median for EBIAT is $136.0 million (2024), against an average of $135.6 million.
  • Biggest five-year swings in EBIAT: crashed 31.32% in 2022 and later surged 54.57% in 2026.
  • Tracing WST's EBIAT over 5 years: stood at $103.0 million in 2022, then skyrocketed by 33.01% to $137.0 million in 2023, then decreased by 5.04% to $130.1 million in 2024, then rose by 1.54% to $132.1 million in 2025, then grew by 5.07% to $138.8 million in 2026.
  • According to Business Quant data, EBIAT over the past three periods came in at $138.8 million, $132.1 million, and $140.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.